SRZN
Surrozen, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-1.09
P/S
58.92
EV/EBITDA
-1.19
DCF Value
$11.41
FCF Yield
-14.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.7%
Operating Margin
-1210.6%
Net Margin
-6960.8%
ROE
610.8%
ROA
-245.1%
ROIC
-46.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $528.0K | $-183.2M | $-23.87 |
| FY 2025 | $3.5M | $-242.0M | $-32.37 |
| Q3 2025 | $983.0K | $-71.6M | $-8.36 |
| Q2 2025 | $983.0K | $39.7M | $2.55 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.52
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.